Neuroendocrine Cancer | Tumor

CURE’s neuroendocrine cancer page features the latest cancer news and updates on neuroendocrine cancer Through articles, videos, podcasts, and more, CURE brings readers the insights of experts, cancer survivors, patients, and advocates to ensure everyone is up to date in neuroendocrine cancer.

Expert Advice and Resources for Patients with Neuroendocrine Tumors

November 24th 2025, 2:00pm

Video

Dr. Pamela L. Kunz sat down for an interview with CURE to discuss resources and ongoing initiatives that may help patients with this disease.

Understanding the Diagnosis and Treatment of Neuroendocrine Tumors

November 19th 2025, 2:00pm

Article

Dr. Pamela L. Kunz sat down with CURE to discuss Neuroendocrine Tumors, or NETs, Awareness Month.

FDA Approves Welireg for Pheochromocytoma and Paraganglioma

May 14th 2025, 5:02pm

Article

The FDA approved Welireg for adult and pediatric patients 12 and older with locally advanced, unresectable or metastatic pheochromocytoma or paraganglioma.

FDA Approves Cabometyx, Another Treatment for Neuroendocrine Tumors

April 14th 2025, 7:00pm

Article

The FDA has approved Cabometyx for some patients 12 years old and older with previously treated neuroendocrine tumors.

Trial of SVV-001, Opdivo and Yervoy in Neuroendocrine Tumors Launching

April 14th 2025, 3:00pm

Article

A phase 1 clinical trial is open for enrollment to patients with high-grade neuroendocrine tumors.

Phase 3 Trial Leads to FDA Approval of Cabometyx in Neuroendocrine Tumors

April 13th 2025, 2:00pm

Video

Based on the phase 3 CABINET trial, the FDA approved Cabometyx for some patients with previously treated neuroendocrine tumors.

FDA Approves Cabometyx for Some Neuroendocrine Tumors

March 26th 2025, 1:44pm

Article

The FDA has approved Cabometyx for some patients 12 years old and older with pancreatic neuroendocrine tumors and extra-pancreatic neuroendocrine tumors.

177Lu-edotreotide May Delay Progression in Neuroendocrine Tumor Subset

March 7th 2025, 10:00pm

Article

177Lu-edotreotide shows potential to extend progression-free survival in patients with grade 1 or 2 somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors.

ITM-11 Meets Phase 3 Trial Primary End Point of PFS in GEP-NETs

February 2nd 2025, 7:00pm

Article

Topline results from the COMPETE trial showed that ITM-11 met the study’s primary end point of PFS in inoperable, progressive grade 1 or grade 2 GEP-NETs.

FDA Accepts sNDA for Welireg in Advanced Pheochromocytoma and Paraganglioma

January 29th 2025, 2:00pm

Article

The FDA has accepted a priority review sNDA for Welireg in adults and pediatric patients with advanced or metastatic pheochromocytoma and paraganglioma.